Cancer drug business.
Concordia in the news
Posted on June 16, 2016
Expert commentators
Concordia faculty and researchers are regularly asked to offer expert, informed opinions on many of today's most pressing problems. Read some of the latest news items about Concordians:
- Yahoo! Finance quotes Lea Prevel Katsanis, marketing professor in the John Molson School of Buisness, in an article about the possiblity that regulatory constraints and market forces may compel Spectrum Pharmaceuticals to halt production of Zevalin, a cancer drug noted for its benefits to patients with non-Hodgkin's Lymphoma. The article references Katsanis' book, Global Issues in Pharmaceutical Marketing (Routledge, 2015).